$TCRT
Alaunos Therapeutics, Inc.

2014 Q3 Form 10-Q Financial Statement

#000119312514300632 Filed on August 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $630.0K $200.0K $200.0K
YoY Change 215.0% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.840M $3.030M $3.720M
YoY Change -7.49% -18.55% -24.08%
% of Gross Profit
Research & Development $9.733M $8.346M $14.78M
YoY Change 55.8% -43.51% -19.1%
% of Gross Profit
Depreciation & Amortization $120.0K $100.0K $200.0K
YoY Change -33.33% -50.0% 33.33%
% of Gross Profit
Operating Expenses $9.733M $8.346M $14.78M
YoY Change 55.8% -43.51% -19.1%
Operating Profit -$11.94M -$11.18M -$18.30M
YoY Change 31.01% -38.91% -20.33%
Interest Expense $5.850M $5.600M -$400.0K
YoY Change -178.95% -1500.0% -38.46%
% of Operating Profit
Other Income/Expense, Net $2.000K $1.000K $7.000K
YoY Change -101.05% -85.71% 133.33%
Pretax Income -$6.090M -$5.580M -$18.69M
YoY Change -63.55% -70.14% -20.84%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.093M -$5.576M -$18.69M
YoY Change -63.54% -70.17% -20.84%
Net Earnings / Revenue -967.14% -2788.0% -9346.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.06 -$0.06 -$0.22
COMMON SHARES
Basic Shares Outstanding 100.7M shares 100.7M shares 83.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.10M $53.00M $38.90M
YoY Change 95.34% 36.25% -64.76%
Cash & Equivalents $46.12M $53.00M $38.93M
Short-Term Investments
Other Short-Term Assets $1.500M $1.000M $4.100M
YoY Change -53.13% -75.61% -54.95%
Inventory
Prepaid Expenses
Receivables $200.0K $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $47.81M $54.02M $43.03M
YoY Change 75.3% 25.55% -63.96%
LONG-TERM ASSETS
Property, Plant & Equipment $654.0K $683.0K $1.713M
YoY Change -51.05% -60.13% -14.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $513.0K $513.0K $732.0K
YoY Change -30.58% -29.92% -26.8%
Total Long-Term Assets $1.295M $1.324M $2.573M
YoY Change -41.22% -48.54% -14.23%
TOTAL ASSETS
Total Short-Term Assets $47.81M $54.02M $43.03M
Total Long-Term Assets $1.295M $1.324M $2.573M
Total Assets $49.11M $55.35M $45.60M
YoY Change 66.6% 21.37% -62.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.953M $447.0K $1.165M
YoY Change 119.19% -61.63% -22.33%
Accrued Expenses $7.803M $7.773M $18.97M
YoY Change -32.58% -59.02% 22.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.70M $10.79M $21.00M
YoY Change -12.44% -48.62% 17.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.00K $20.00K $2.576M
YoY Change 0.0% -99.22% -91.12%
Total Long-Term Liabilities $20.00K $20.00K $2.576M
YoY Change 0.0% -99.22% -91.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.70M $10.79M $21.00M
Total Long-Term Liabilities $20.00K $20.00K $2.576M
Total Liabilities $12.63M $17.63M $26.27M
YoY Change -51.13% -32.88% -43.75%
SHAREHOLDERS EQUITY
Retained Earnings -$362.2M -$356.1M
YoY Change
Common Stock $398.7M $390.3M $330.8M
YoY Change 20.12% 17.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.48M $37.72M $19.33M
YoY Change
Total Liabilities & Shareholders Equity $49.11M $55.35M $45.60M
YoY Change 66.6% 21.37% -62.74%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$6.093M -$5.576M -$18.69M
YoY Change -63.54% -70.17% -20.84%
Depreciation, Depletion And Amortization $120.0K $100.0K $200.0K
YoY Change -33.33% -50.0% 33.33%
Cash From Operating Activities -$10.49M -$7.640M -$16.72M
YoY Change -32.32% -54.31% -0.3%
INVESTING ACTIVITIES
Capital Expenditures $90.00K $100.0K $10.00K
YoY Change 900.0% -98.96%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$90.00K -$100.0K -$10.00K
YoY Change 900.0% -98.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.700M 350.0K 0.000
YoY Change 1750.0% -100.0%
NET CHANGE
Cash From Operating Activities -10.49M -7.640M -16.72M
Cash From Investing Activities -90.00K -100.0K -10.00K
Cash From Financing Activities 3.700M 350.0K 0.000
Net Change In Cash -6.880M -7.390M -16.73M
YoY Change -55.03% -55.83% -5.1%
FREE CASH FLOW
Cash From Operating Activities -$10.49M -$7.640M -$16.72M
Capital Expenditures $90.00K $100.0K $10.00K
Free Cash Flow -$10.58M -$7.740M -$16.73M
YoY Change -31.74% -53.74% -5.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100742889 shares
CY2013Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
65 Position
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38932000
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100725066 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3176594 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.91
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6041162 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5317831 shares
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.11
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10496467 shares
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.11
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5988240 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100725066 shares
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10788000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
447000
CY2014Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
3541000
CY2014Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
37716000
CY2014Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
390192000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356118000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2333000
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7773000
CY2014Q2 us-gaap Liabilities
Liabilities
17632000
CY2014Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
965000
CY2014Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
730000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
101000
CY2014Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
235000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55348000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
513000
CY2014Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6200000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
683000
CY2014Q2 us-gaap Assets
Assets
55348000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53001000
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1846000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4456000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4417000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
991000
CY2014Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
32000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
54024000
CY2014Q2 ziop Warrants Liability
WarrantsLiability
6094000
CY2009Q4 ziop Estimated Fair Value Of Warrant
EstimatedFairValueOfWarrant
22900000
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate
ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate
0.0214 pure
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Stock Volatility
ClassOfWarrantOrRightFairValueAssumptionStockVolatility
1.05 pure
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield
ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield
0.00 pure
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73306000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100159618 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3471935 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6747302 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.01
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10539767 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100159618 shares
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1933000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7791000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
422000
CY2013Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
3603000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
49383000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
386511000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-340831000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6357000
CY2013Q4 us-gaap Liabilities
Liabilities
22371000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
1100000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
851000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
100000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
212000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71754000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
528000
CY2013Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
801000
CY2013Q4 us-gaap Assets
Assets
71754000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68204000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2654000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1948000
CY2013Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
145000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
70297000
CY2013Q4 ziop Warrants Liability
WarrantsLiability
11776000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1426400 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-34964000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82994845 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.89
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17434175 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-4000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
10385000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Interest Paid
InterestPaid
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2845000
us-gaap Contracts Revenue
ContractsRevenue
400000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-269000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41879000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
250000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-27000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
72000
us-gaap Net Income Loss
NetIncomeLoss
-31491000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
705000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8392000
us-gaap Share Based Compensation
ShareBasedCompensation
1673000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
42279000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
396000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-34374000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-11000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
619000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-115000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
101000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2453000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-344000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
854000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33887000
dei Trading Symbol
TradingSymbol
ZIOP
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M27D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
104300 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.54
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16289000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100326416 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>3. Recently Issued Accounting Pronouncements</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> On June&#xA0;10, 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915), which simplifies financial reporting for development stage entities by eliminating requirements specific to development stage entities. As a result, entities in a development stage will no longer need to present inception-to-date information about income statement line items, cash flows, and equity transactions. Instead, the new guidance clarifies how these entities should tailor existing disclosures to explain the risks and uncertainties related to their activities. This update is effective for annual periods beginning after December&#xA0;15, 2014, and early application is permitted for any annual or interim period for which the entity&#x2019;s financial statements have not yet been issued. The Company adopted this guidance prior to issuing the financial statements in this Quarterly Report on Form 10-Q. The adoption of ASU 2014-10 impacted presentation and disclosure only and did not have any impact on financial position or results of operations.</p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y7M10D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
583038 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
227402 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16833125 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M10D
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5682000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1317000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Interest Paid
InterestPaid
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-957000
us-gaap Contracts Revenue
ContractsRevenue
400000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20961000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
132000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-113000
us-gaap Net Income Loss
NetIncomeLoss
-15287000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
62000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1185000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2435000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14888000
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6473000
us-gaap Share Based Compensation
ShareBasedCompensation
2435000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21361000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
132000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
217000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15203000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-98000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
305000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-99000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1416000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
25000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1317000
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2009 ziop Class Of Warrant Or Right Fair Value Assumption Expected Life
ClassOfWarrantOrRightFairValueAssumptionExpectedLife
P5Y
CY2009 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11D
CY2013 ziop Revenue Recognition Period
RevenueRecognitionPeriod
P75M
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1315500 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9545 pure
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83082633 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.77
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-403000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2013Q2 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18296000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-18692000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3721000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
132000
CY2013Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
18496000
CY2013Q2 us-gaap Severance Costs1
SeveranceCosts1
1700000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14775000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
23800 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9407 pure
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100422564 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.84
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5600000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11177000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-5576000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3031000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1212000
CY2014Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
11377000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8346000

Files In Submission

Name View Source Status
0001193125-14-300632-index-headers.html Edgar Link pending
0001193125-14-300632-index.html Edgar Link pending
0001193125-14-300632.txt Edgar Link pending
0001193125-14-300632-xbrl.zip Edgar Link pending
d761422d10q.htm Edgar Link pending
d761422dex101.htm Edgar Link pending
d761422dex311.htm Edgar Link pending
d761422dex312.htm Edgar Link pending
d761422dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g761422tx_pg001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20140630.xml Edgar Link completed
ziop-20140630.xsd Edgar Link pending
ziop-20140630_cal.xml Edgar Link unprocessable
ziop-20140630_def.xml Edgar Link unprocessable
ziop-20140630_lab.xml Edgar Link unprocessable
ziop-20140630_pre.xml Edgar Link unprocessable